Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 11/20 | 0.44 |
| ▸ | PTPN2 | P17706 | 9/20 | 0.44 |
| ▸ | CDC25B | P30305 | 9/20 | 0.44 |
| ▸ | PARP15 | Q460N3 | 3/20 | 0.43 |
| ▸ | PARP10 | Q53GL7 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.41 |
| ▸ | F9 | P00740 | 1/20 | 0.41 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30656154 | 1.00 | SCN9A (0.44) | SCN9APTPN1PTPN2CDC25BPARP15 | |
| SCHEMBL30656254 | 0.89 | SCN9A (0.52) | SCN9APTPN1PTPN2CDC25BPARP15 | |
| SCHEMBL30656003 | 0.89 | SCN9A (0.52) | SCN9APTPN1PTPN2CDC25BPARP15 | |
| SCHEMBL26792926 | 0.86 | SCN9A (0.33) | SCN9A | |
| SCHEMBL30656325 | 0.86 | SCN9A (0.33) | SCN9A | |
| SCHEMBL30656198 | 0.86 | SCN9A (0.33) | SCN9A | |
| SCHEMBL30656176 | 0.85 | CD38 (0.36) | SCN9AMAOB | |
| SCHEMBL30656016 | 0.85 | CD38 (0.36) | SCN9AMAOB | |
| SCHEMBL30656105 | 0.84 | CD274 (0.34) | PARP15PARP10 | |
| SCHEMBL26793645 | 0.84 | CD274 (0.34) | PARP15PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346569-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-11-13 | — | — | US | claimed |
| EP-4532013-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-04-09 | — | — | EP | claimed |
| WO-2023227697-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | claimed |
| US-20250346569-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-11-13 | — | — | US | disclosed |
| EP-4532013-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | Katholieke Universiteit Leuven KU Leuven Research & Development (BE) | 2025-04-09 | — | — | EP | disclosed |
| WO-2023227697-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250346569-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM4, TRPM2, TRPM6 | SCN9A 256/4885PTPN1 4273/4885PTPN2 4065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.